Volume 27, Number 1—January 2021
Synopsis
Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan
Iacopo Baussano
, Felix Sayinzoga, Ugyen Tshomo, Vanessa Tenet, Alex Vorsters, Daniëlle A.M. Heideman, Tarik Gheit, Massimo Tommasino, Marie Chantal Umulisa, Silvia Franceschi, and Gary M. Clifford
, Felix Sayinzoga, Ugyen Tshomo, Vanessa Tenet, Alex Vorsters, Daniëlle A.M. Heideman, Tarik Gheit, Massimo Tommasino, Marie Chantal Umulisa, Silvia Franceschi, and Gary M. Clifford
Table 1
Comparison of female students in HPV surveys, by selected characteristics, Rwanda baseline (2013–2014) and repeat (2017) surveys and Bhutan baseline (2013) and repeat (2017) surveys*
| Characteristic | Rwanda |
Bhutan |
|||
|---|---|---|---|---|---|
| Baseline survey | Repeat survey | Baseline survey | Repeat survey | ||
| All |
912 |
1,087 |
973 |
909 |
|
| Age-group, y | |||||
| 17–18 | 374 (41.0) | 536 (49.3) | 285 (29.3) | 347 (38.2) | |
| 19 | 274 (30.0) | 326 (30.0) | 337 (34.6) | 303 (33.3) | |
| 20–22 | 264 (29.0) | 225 (20.7) | 351 (36.1) | 259 (28.5) | |
| χ2 |
p<0.001 |
p<0.001 |
|||
| Place of birth | |||||
| Capital | 497 (54.5) | 800 (73.6) | 309 (31.8) | 315 (34.7) | |
| Outside capital | 415 (45.5) | 287 (26.4) | 663 (68.2) | 594 (65.3) | |
| χ2 |
p<0.001 |
p = 0.187 |
|||
| Place of living | |||||
| With family or relative | 763 (83.7) | 936 (86.1) | 798 (82.0) | 765 (84.2) | |
| Boarding school | 149 (16.3) | 151 (13.9) | 175 (18.0) | 144 (15.8) | |
| χ2 |
p = 0.127 |
p = 0.215 |
|||
| History of sexual intercourse | |||||
| Never | 720 (79.0) | 729 (67.1) | 871 (89.5) | 760 (83.6) | |
| Ever or prefer not to answer† | 192 (21.0) | 358 (32.9) | 102 (10.5) | 149 (16.4) | |
| χ2 |
p<0.001 |
p<0.001 |
|||
| Chlamydia trachomatis‡ | |||||
| Negative | 892 (97.8) | 1047 (96.3) | 940 (96.6) | 872 (95.9) | |
| Positive | 20 (2.2) | 40 (3.7) | 33 (3.4) | 37 (4.1) | |
| χ2 |
p = 0.052 |
p = 0.437 |
|||
| HPV vaccination | |||||
| No | 519 (56.9) | 125 (11.5) | 77 (7.9) | 45 (5.0) | |
| Yes | 393 (43.1) | 962 (88.5) | 896 (92.1) | 864 (95.0) | |
| χ2 |
p<0.001 |
p = 0.009 |
|||
| Age at vaccination§ | |||||
| <14 | 12 (3.1) | 412 (46.5) | 12 (2.0) | 569 (87.4) | |
| >14 | 378 (96.9) | 474 (53.5) | 591 (98.0) | 82 (12.6) | |
| χ2 |
p<0.001 |
p<0.001 |
|||
| No. doses§ | |||||
| 1 | NA | 52 (5.5) | NA | 84 (9.9) | |
| 2–3 | NA | 901 (94.5) | NA | 769 (90.2) | |
*Values are no. (%) except as indicated. HPV, human papillomavirus; NA, not assessed. †Includes 4 (Rwanda baseline), and 38 (Rwanda repeat), 43 (Bhutan baseline), and 20 (Bhutan repeat) students who preferred not to answer this question. ‡Detected by using E7 PCR bead-based multiplex genotyping assay. §Does not add up to the total because of missing values.
Page created: November 03, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.